IBIO INC (IBIO:NASDAQ)
$2.24 0.08 (3.7037%)
Analysed IBIO INC (IBIO:NASDAQ) News Sources
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
08-04-2026
marketbeat.com
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
08-04-2026
yahoo.com
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
20-03-2026
marketbeat.com
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
16-03-2026
yahoo.com
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
09-03-2026
yahoo.com
iBio to Participate in Upcoming Investor Conferences
24-02-2026
yahoo.com
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
10-02-2026
yahoo.com
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
03-02-2026
yahoo.com
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
02-02-2026
yahoo.com
iBio Announces $26 Million Private Placement
09-01-2026
yahoo.com
What is the current price of IBIO INC (IBIO:NASDAQ)?
The current price of IBIO INC (IBIO:NASDAQ) is $2.24.
IBIO INC (IBIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of IBIO INC (IBIO:NASDAQ) since the previous trading day is $0.08.
IBIO INC (IBIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of IBIO INC (IBIO:NASDAQ) since the previous trading day is 3.7037%.
What is the most recent average sentiment score for IBIO INC (IBIO:NASDAQ)?
The most recent average sentiment score for IBIO INC (IBIO:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for IBIO INC (IBIO:NASDAQ)?
The most recent sentiment for IBIO INC (IBIO:NASDAQ) is .
SEC-8K** Filing Available For IBIO INC (IBIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.